To the full analysis
Evommune stock: growth
EVMNEvommune reported $13M in revenue for fiscal 2025, up 85.7% on the prior year.
Revenue (Annual rate)
61.2%
per year from 2023 to 2025, per share 257%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2023 | |
|---|---|
| Revenue | 61.2% |
| Revenue per share | 257.0% |
| Earnings | no data |
| Earnings per share | no data |
| Free cash flow | no data |
| Free cash flow per share | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2023 | $5M | −$34.05M | −$30.09M |
| 2024 | $7M | −$66.81M | −$58.28M |
| 2025 | $13M | −$68.87M | −$76.68M |
Data status and sources
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 6 Nov 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.